SOUTH SAN FRANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Steven P. James, senior vice president, commercial operations, will present at the upcoming Friedman Billings Ramsey 8th Annual Growth Investor Conference at 10:00 am (Eastern Time) on Thursday, June 3, 2004.

The presentation will be webcast and may be accessed in the Events page under Investor Information on the Exelixis website at http://www.exelixis.com/index.asp?secPage=events .

About Exelixis, Inc.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline includes: XL119, which is anticipated to enter a Phase 3 clinical trial as a potential treatment for bile duct tumors; XL784, which has completed a Phase 1 clinical trial; XL647, an anticancer compound that is anticipated to enter a Phase 1 clinical trial; XL999, XL844, XL820 and XL880, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb Company. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company's web site at www.exelixis.com.

SOURCE  Exelixis, Inc.
    -0-                             05/26/2004
    /CONTACT:  Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis,
Inc., +1-650-837-7579, or jmgreen@exelixis.com/
    /Web site:  http://www.exelixis.com /
    (EXEL)

CO:  Exelixis, Inc.
ST:  California
IN:  MTC BIO HEA
SU:  CCA TDS

HD 
-- SFW080 --
3955 05/26/2004 16:00 EDT http://www.prnewswire.com